Edelman Joseph's Form 4 filing
Verrica Pharmaceuticals Inc. (VRCA) · filed Dec 19, 2023
- Accession no.
- 0001062993-23-022861
- Filed
- Dec 19, 2023, 5:52 PM ET
- Trade date
- Dec 15-19, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $6.94M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | 10% Owner |
| Perceptive Advisors LLCCIK 0001224962 | 10% Owner |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2023 | Common Stock | PPurchaseAcquired | +500,000 | $5.97 | +$2,985,000 | 5,538,983 | Indirect | |
| Dec 18, 2023 | Common Stock | PPurchaseAcquired | +456,923 | $5.41 | +$2,471,953.43 | 5,995,906 | Indirect | |
| Dec 19, 2023 | Common Stock | PPurchaseAcquired | +277,008 | $5.36 | +$1,484,762.88 | 6,272,914 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.